|
Solid State Kinetics of Nitrosation Using Native Sources of Nitrite -Pub
|
|
1
|
1076
|
March 6, 2023
|
|
Current threat of nitrosamines in pharmaceuticals and scientific strategies for risk mitigation -Pub
|
|
0
|
943
|
February 7, 2023
|
|
2 years after pushing FDA to analyze Nitrosamines, Valisure cited it for failing to comply with federal law
|
|
3
|
515
|
February 15, 2023
|
|
Carry over limits for Niitrsoamines
|
|
2
|
738
|
February 12, 2023
|
|
N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations -Pub
|
|
0
|
1327
|
February 7, 2023
|
|
A bioanalytical method for N-nitrosodimethylamine (NDMA) in human samples following ranitidine -Pub
|
|
0
|
579
|
February 7, 2023
|
|
Nitrosated active pharmaceutical ingredients – lessons learned -Pub
|
|
0
|
748
|
February 7, 2023
|
|
The impact of N-nitrosamine impurities on clinical drug development -Pub
|
|
1
|
621
|
February 3, 2023
|
|
Nitrosamine Impurities -Reg Updates Publication
|
|
0
|
865
|
February 1, 2023
|
|
An update on the current status of possible roots causes of Nitrosamines
|
|
2
|
1012
|
January 28, 2023
|
|
Crisis management of the mass losartan recall in a public primary healthcare institution in Singapore
|
|
0
|
419
|
January 9, 2023
|
|
FDA - A new structural similarity method to ID surrogate compounds of Nitroamines
|
|
5
|
1915
|
January 7, 2023
|
|
A substructure-based screening approach to uncover Nnitrosamines in drug substances
|
|
0
|
584
|
October 10, 2022
|
|
Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines -published
|
|
0
|
502
|
September 8, 2022
|
|
NAs positive in Ames test without metabolic activation
|
|
2
|
540
|
November 29, 2022
|
|
A new study on nitrite scavengers for nitrosamine formation prevention
|
|
0
|
546
|
November 17, 2022
|
|
Predicting DNA-reactivity of N-nitrosamines: Quantum Chemical Approach
|
|
0
|
288
|
November 16, 2022
|
|
NitrosAMIDES - Should they be treated the same as Nitrosamines?
|
|
1
|
802
|
October 25, 2022
|
|
N-Nitrosation in the absence of nitrosating agents in pharmaceuticals?
|
|
2
|
571
|
September 27, 2022
|
|
Formation of the N-nitroso Deviratives of six b-Adrenergic-blocking 'LOL'
|
|
0
|
461
|
September 22, 2022
|
|
Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines
|
|
0
|
356
|
August 23, 2022
|
|
Journal of Pharmaceutical Sciences is dedicating a Special Issue to the topic of nitrosamine impurities in drugs
|
|
1
|
516
|
August 2, 2022
|
|
Disinfected water and Nitrosamines
|
|
3
|
667
|
July 22, 2022
|
|
International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin‑Containing Medicines
|
|
0
|
368
|
May 6, 2022
|
|
Salmonella typhimurium are highly sensitive to detect the mutagenicity of short Alkyl-N-Nitrosamines in the Bacterial Reverse Mutation Test
|
|
0
|
216
|
May 24, 2022
|
|
EMA Nitrosamine Implementation Oversight Meeting Highlights Mar'22
|
|
0
|
424
|
March 31, 2022
|
|
CMHP meeting from January: N-nitroso-Mefanamic Acid & N-Nitroso-Folic Acid
|
|
6
|
1099
|
April 25, 2022
|
|
Bacterial reverse mutation assay suitable to detect the mutagenicity of Nitrosamines
|
|
0
|
253
|
February 14, 2022
|
|
Azido Impurity Method LC-MS/MS
|
|
0
|
355
|
March 25, 2022
|
|
IPEC Federation Position Paper on Role of Excipients in determining N-Nitrosamine Risks for Drug Products - Thoughts?
|
|
1
|
391
|
March 7, 2022
|